ESC/EACTS Guidelines on the management of valvular heart disease (version 2012)

ESC/EACTS Guidelines on the management of valvular heart disease (version 2012)

2012 | Alec Vahanian (Chairperson) (France)*, Ottavio Alfieri (Chairperson)* (Italy), Felicita Andreotti (Italy), Manuel J. Antunes (Portugal), Gonzalo Barón-Esquivas (Spain), Helmut Baumgartner (Germany), Michael Andrew Borger (Germany), Thierry P. Carrel (Switzerland), Michele De Bonis (Italy), Arturo Evangelista (Spain), Volkmar Falk (Switzerland), Bernard Jurg (France), Patrizio Lancellotti (Belgium), Luc Pierard (Belgium), Susanna Price (UK), Hans-Joachim Schäfers (Germany), Gerhard Schuler (Germany), Janina Stepinska (Poland), Karl Swedberg (Sweden), Johanna Takkenberg (The Netherlands), Ulrich Otto Von Oppell (UK), Stephan Windecker (Switzerland), Jose Luis Zamorano (Spain), Marian Zembala (Poland)
The guidelines provide a comprehensive overview of the management of valvular heart disease (VHD), focusing on acquired VHD and excluding endocarditis and congenital valve disease. They are intended to assist healthcare professionals in making informed decisions about the diagnosis and treatment of VHD, considering the latest evidence and expert consensus. The guidelines cover various aspects, including patient evaluation, risk stratification, management of associated conditions, and specific considerations for different types of VHD such as aortic regurgitation (AR), aortic stenosis (AS), mitral regurgitation (MR), mitral stenosis, tricuspid regurgitation, and tricuspid stenosis. They emphasize the importance of a multidisciplinary approach involving cardiologists, cardiac surgeons, imaging specialists, and other specialists. The guidelines also address the use of non-invasive and invasive diagnostic methods, the role of prophylaxis, and the management of comorbidities. Additionally, they provide detailed recommendations for surgical and medical interventions, including the selection of appropriate procedures based on patient characteristics and the potential benefits and risks. The guidelines aim to improve the quality of care and outcomes for patients with VHD by providing clear and evidence-based recommendations.The guidelines provide a comprehensive overview of the management of valvular heart disease (VHD), focusing on acquired VHD and excluding endocarditis and congenital valve disease. They are intended to assist healthcare professionals in making informed decisions about the diagnosis and treatment of VHD, considering the latest evidence and expert consensus. The guidelines cover various aspects, including patient evaluation, risk stratification, management of associated conditions, and specific considerations for different types of VHD such as aortic regurgitation (AR), aortic stenosis (AS), mitral regurgitation (MR), mitral stenosis, tricuspid regurgitation, and tricuspid stenosis. They emphasize the importance of a multidisciplinary approach involving cardiologists, cardiac surgeons, imaging specialists, and other specialists. The guidelines also address the use of non-invasive and invasive diagnostic methods, the role of prophylaxis, and the management of comorbidities. Additionally, they provide detailed recommendations for surgical and medical interventions, including the selection of appropriate procedures based on patient characteristics and the potential benefits and risks. The guidelines aim to improve the quality of care and outcomes for patients with VHD by providing clear and evidence-based recommendations.
Reach us at info@study.space
[slides] Guidelines on the Management of Valvular Heart disease (Version 2012) | StudySpace